News
FDA Review of Ingredient Rules Could Shape the ...
FDA Review of Ingredient Rules Could Shape the Next Supplement Wave By Himiyer News | April 7, 2026 Table of Contents What Happened Why It Matters for Buyers What to...
FDA Review of Ingredient Rules Could Shape the ...
FDA Review of Ingredient Rules Could Shape the Next Supplement Wave By Himiyer News | April 7, 2026 Table of Contents What Happened Why It Matters for Buyers What to...
Shilajit Is Booming, but Quality Questions Are ...
Shilajit Is Booming, but Quality Questions Are Rising With It By Himiyer News | April 7, 2026 Table of Contents What Happened Why It Matters for Buyers What to Watch...
Shilajit Is Booming, but Quality Questions Are ...
Shilajit Is Booming, but Quality Questions Are Rising With It By Himiyer News | April 7, 2026 Table of Contents What Happened Why It Matters for Buyers What to Watch...
FDA Warns 30 Telehealth Companies Over Compound...
FDA Warns 30 Telehealth Companies Over Compounded GLP-1 Marketing By Himiyer News | April 7, 2026 Table of Contents What Happened Why It Matters for Buyers What to Watch Next...
FDA Warns 30 Telehealth Companies Over Compound...
FDA Warns 30 Telehealth Companies Over Compounded GLP-1 Marketing By Himiyer News | April 7, 2026 Table of Contents What Happened Why It Matters for Buyers What to Watch Next...
FDA Signals a Harder Line on Copycat GLP-1 Prod...
The FDA is drawing a firmer line around non-approved GLP-1 copycats. For supplement and wellness shoppers, that means more reason to question pages that blur the difference between approved drugs...
FDA Signals a Harder Line on Copycat GLP-1 Prod...
The FDA is drawing a firmer line around non-approved GLP-1 copycats. For supplement and wellness shoppers, that means more reason to question pages that blur the difference between approved drugs...
FDA Public Meeting Signals Fresh Scrutiny of Wh...
One of the most important policy stories in supplements this quarter is not a recall. It is FDA’s March 2026 public meeting on the scope of dietary supplement ingredients under...
FDA Public Meeting Signals Fresh Scrutiny of Wh...
One of the most important policy stories in supplements this quarter is not a recall. It is FDA’s March 2026 public meeting on the scope of dietary supplement ingredients under...
FDA Tells Divine Rx That Supplement Products Cr...
By Himiyer | March 27, 2026 Table of Contents What Happened Why It Matters What Buyers Should Do What Happened FDA said in a March 2026 online advisory letter that...
FDA Tells Divine Rx That Supplement Products Cr...
By Himiyer | March 27, 2026 Table of Contents What Happened Why It Matters What Buyers Should Do What Happened FDA said in a March 2026 online advisory letter that...
